Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTolcapone
Description: COMT inhibitor; also inhibits transthyretin aggregation
Alternative Names: Tasmar,Ro 40-7592
Chemical Name: (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
Purity: ≥99% (HPLC)
Biological Activity for Tolcapone
Tolcapone is a COMT inhibitor. Inhibits both brain and peripheral COMT. Also binds transthyretin (TTR) with high affinity (Kd1 and Kd2 values are 21 and 58 nM, respectively). Inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo. Orally bioavailable.
Technical Data for Tolcapone
| M. Wt | 273.24 |
| Formula | C14H11NO5 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 134308-13-7 |
| PubChem ID | 4659569 |
| InChI Key | MIQPIUSUKVNLNT-UHFFFAOYSA-N |
| Smiles | OC1=C(O)C([N+]([O-])=O)=CC(C(C2=CC=C(C)C=C2)=O)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Tolcapone
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| ethanol | 27.32 | 100 | |
| DMSO | 27.32 | 100 |
Preparing Stock Solutions for Tolcapone
The following data is based on the product molecular weight 273.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.66 mL | 18.3 mL | 36.6 mL |
| 5 mM | 0.73 mL | 3.66 mL | 7.32 mL |
| 10 mM | 0.37 mL | 1.83 mL | 3.66 mL |
| 50 mM | 0.07 mL | 0.37 mL | 0.73 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Tolcapone
References for Tolcapone
References are publications that support the biological activity of the product.
Sant'Anna et al (2016) Repositioning tolc. as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat.Commun. 7 10787 PMID: 26902880
Männistö et al (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br.J.Pharmacol. 105 569 PMID: 1628144
If you know of a relevant reference for Tolcapone, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tolcapone, Tolcapone supplier, catechol, O-methyl, transferase, inhibitors, inhibits, COMT, orally, bioavailable, high, affinity, TTR, binding, transthyretin, aggregation, Ro40-7592, Tasmar, Ro, 40-7592, Catechol, O-Methyltransferase, 5864, Tocris Bioscience
Citations for Tolcapone
Citations are publications that use Tocris products.
Currently there are no citations for Tolcapone. Do you know of a great paper that uses Tolcapone from Tocris? Please let us know.
Reviews for Tolcapone
There are currently no reviews for this product. Be the first to review Tolcapone and earn rewards!
Have you used Tolcapone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.